Skip to main content
PMC home page
Cancer Science logoLink to Cancer Science
. 2005 Aug 19;94(1):15–21. doi: 10.1111/j.1349-7006.2003.tb01345.x

Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal

Takashi Tsuruo 1,2,✉, Mikihiko Naito 1, Akihiro Tomida 1, Naoya Fujita 1, Tetsuo Mashima 2, Hiroshi Sakamoto 1,2, Naomi Haga 1
PMCID: PMC11160265  PMID: 12708468

Abstract

Recent progress in the development of molecular cancer therapeutics has revealed new types of antitumor drugs, such as Herceptin, Gleevec, and Iressa, as potent therapeutics for specific tumors. Our work has focused on molecular cancer therapeutics, mainly in the areas of drug resistance, apoptosis and apoptosis resistance, and survival‐signaling, which is related to drug resistance. In this review, we describe our research on molecular cancer therapeutics, including molecular mechanisms and therapeutic approaches. Resistance to chemotherapeutic drugs is a principal problem in the treatment of cancer. P‐Glycoprotein (P‐gp), encoded by the MDR1 gene, is a multidrug transporter and has a major role in multidrug resistance (MDR). Targeting of P‐gp by small‐molecular compounds and/or antibodies is an effective strategy to overcome MDR in cancer, especially hematologic malignancies. Several P‐gp inhibitors have been developed and are currently under clinical phased studies. In addition to the multi‐drug transporter proteins, cancer cells have several drug resistance mechanisms. Solid tumors are often placed under stress conditions, such as glucose starvation and hypoxia. These conditions result in topo II poison resistance that is due to proteasome‐mediated degradation of DNA topoisomerases. Proteasome inhibitors effectively prevent this stress‐induced drug resistance. Glyoxalase I, which is often elevated in drug‐ and apoptosis‐resistant cancers, offers another possibility for overcoming drug resistance. It plays a role in detoxification of methylglioxal, a side product of glycolysis, which is highly reactive with DNA and proteins. Inhibitors of glyoxalase I selectively kill drug‐resistant tumors that express glyoxalase I. Finally, the susceptibility of tumor cells to apoptosis induced by antitumor drugs appears to depend on the balance between pro‐apoptotic and survival (anti‐apoptotic) signals. PI3K‐Akt is an important survival signal pathway, that has been shown to be the target of various antitumor drugs, including UCN‐01 and geldanamycin, new anticancer drugs under clinical evaluation. Our present studies provide novel targets for future effective molecular cancer therapeutics. (Cancer Sci 2003; 94: 15–21)

References

  • 1. Tsuruo T. Mechanisms of multidrug resistance and implications for therapy. Jpn J Cancer Res 1988; 79: 285–96. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2. Sugimoto Y, Tsuruo T. DNA‐mediated transfer and cloning of a human mul‐tidrug‐resistant gene of Adriamycin‐resistant myelogenous leukemia K562. Cancer Res 1987; 47: 2620–5. [PubMed] [Google Scholar]
  • 3. Hamada H, Tsuruo T. Functional role for the 170‐ to 180‐kDa glycoprotein specific to drug‐resistant tumor cells as revealed by monoclonal antibodies. Proc Natl Acad Sci USA 1986; 83: 7785–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4. Hamada H, Tsuruo T. Purification of the 170‐ to 180‐kilodalton membrane glycoprotein associated with multidrug resistance. J Biol Chem 1988; 263: 1454–8. [PubMed] [Google Scholar]
  • 5. Naito M, Hamada H, Tsuruo T. ATP/Mg2+‐dependent binding of vincristine to the plasma membrane of multidrug‐resistant K562 cells. J Biol Chem 1988; 263: 11887–91. [PubMed] [Google Scholar]
  • 6. Tsuruo T, Lida H, Tsukagoshi S, Sakurai Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res 1981; 41: 1967–72. [PubMed] [Google Scholar]
  • 7. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Increased accumulation of vincristine and adriamycin in drug resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res 1982; 42: 4730–3. [PubMed] [Google Scholar]
  • 8. Tsuruo T, Iida H, Tsukagoshi S, Sakurai Y. Potentiation of vincristine and adriamycin effects in human hemopoietic tumor cell lines by calcium antagonists and calmodulin inhibitors. Cancer Res 1983; 43: 2267–72. [PubMed] [Google Scholar]
  • 9. Tsuruo T, Iida H, Nojiri M, Tsukagoshi S, Sakurai Y. Circumvention of vincristine and adriamycin resistance in vitro and in vivo by calcium influx blockers. Cancer Res 1983; 43: 2905–10. [PubMed] [Google Scholar]
  • 10. Sato W, Fukazawa N, Nakanishi O, Baba M, Suzuki T, Yano O, Naito M, Tsuruo T. Reversal of multidrug resistance by a novel quinoline derivative, MS‐209. Cancer Chemother Pharmacol 1995; 35: 271–7. [DOI] [PubMed] [Google Scholar]
  • 11. Natio M, Tsuruo T. Competitive inhibition by verapamil of ATP‐dependent high affinity vincristine binding to the plasma membrane of multidrug‐resistant K562 cells without calcium ion involvement. Cancer Res 1989; 49: 1452–5. [PubMed] [Google Scholar]
  • 12. Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug‐resistance gene product P‐glycoprotein in normal tissues. Proc Natl Acad Sci USA 1987; 84: 7735–8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13. Tatsuta T, Naito M, Oh‐hara T, Sugawara I, Tsuruo T. Functional involvement of P‐glycoprotein in blood‐brain barrier. J Biol Chem 1992; 267: 20383–91. [PubMed] [Google Scholar]
  • 14. Hamada H, Miura K, Ariyoshi K, Heike Y, Sato S, Kameyama K, Kurosawa Y, Tsuruo T. Mouse‐human chimeric antibody against the multidrug transporter P‐glycoprotein. Cancer Res 1990; 50: 3167–71. [PubMed] [Google Scholar]
  • 15. Watanabe T, Naito M, Kokubo N, Tsuruo T. Regression of established tumors expressing P‐glycoprotein by combinations of adriamycin, cyclosporin derivatives, and MRK‐16 antibodies. J Natl Cancer Inst 1997; 89: 512–8. [DOI] [PubMed] [Google Scholar]
  • 16. Sugimoto Y, Sato S, Tsukahara S, Suzuki M, Okochi E, Gottesman MM, Pastan I, Tsuruo T. Coexpression of a multidrug resistance gene (MDR1) and herpes simplex virus thymidine kinase gene in a bicistronic retroviral vector Ha‐MDR‐IRES‐TK allows selective killing of MDR1‐transduced human tumors transplanted in nude mice. Cancer Gene Ther 1997; 4: 51–8. [PubMed] [Google Scholar]
  • 17. Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. Cancer Res 1998; 58: 1408–16. [PubMed] [Google Scholar]
  • 18. Tomida A, Tsuruo T. Drug resistance mediated by cellular stress response to the microenvironment of solid tumors. Anticancer Drug Des 1999; 14: 169–77. [PubMed] [Google Scholar]
  • 19. Kaufman RJ, Scheuner D, Schroder M, Shen X, Lee K, Liu CY, Arnold SM. The unfolded protein response in nutrient sensing and differentiation. Nat Rev Mol Cell Biol 2002; 3: 411–21. [DOI] [PubMed] [Google Scholar]
  • 20. Shen J, Hughes C, Chao C, Cai J, Bartels C, Gessner T, Subjeck J. Coinduc‐tion of glucose‐regulated proteins and doxorubicin resistance in Chinese hamster cells. Proc Natl Acad Sci USA 1987; 84: 3278–82. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21. Yun J, Tomida A, Nagata K, Tsuruo T. Glucose‐regulated stresses confer resistance to VP‐16 in human cancer cells through a decreased expression of DNA topoisomerase II. Oncol Res 1995; 7: 583–90. [PubMed] [Google Scholar]
  • 22. Rubin EH, Li TK, Duann P, Liu LF. Cellular resistance to topoisomerase poisons. Cancer Treat Res 1996; 87: 243–60. [DOI] [PubMed] [Google Scholar]
  • 23. Kim HD, Tomida A, Ogiso Y, Tsuruo T. Glucose‐regulated stresses cause degradation of DNA topoisomerase IIalpha by inducing nuclear proteasome during G1 cell cycle arrest in cancer cells. J Cell Physiol 1999; 180: 97–104. [DOI] [PubMed] [Google Scholar]
  • 24. Ogiso Y, Tomida A, Lei S, Omura S, Tsuruo T. Proteasome inhibition circumvents solid tumor resistance to topoisomerase II‐directed drugs. Cancer Res 2000; 60: 2429–34. [PubMed] [Google Scholar]
  • 25. Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002; 8: S49–54. [DOI] [PubMed] [Google Scholar]
  • 26. Ogiso Y, Tomida A, Kim HD, Tsuruo T. Glucose starvation and hypoxia induce nuclear accumulation of proteasome in cancer cells. Biochem Biophys Res Commun 1999; 258: 448–52. [DOI] [PubMed] [Google Scholar]
  • 27. Ogiso Y, Tomida A, Tsuruo T. Nuclear localization of proteasomes participates in stress‐inducible resistance of solid tumor cells to topoisomerase II‐directed drugs. Cancer Res 2002; 62: 5008–12. [PubMed] [Google Scholar]
  • 28. Horie K, Tomida A, Sugimoto Y, Yasugi T, Yoshikawa H, Taketani Y, Tsuruo T. SUMO‐1 conjugation to intact DNA topoisomerase I amplifies cleavable complex formation induced by camptothecin. Oncogene 2002; 21: 7913–22. [DOI] [PubMed] [Google Scholar]
  • 29. Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res 2000; 256: 42–9. [DOI] [PubMed] [Google Scholar]
  • 30. Kataoka S, Naito M, Tomida A, Tsuruo T. Resistance to antitumor agent‐induced apoptosis in a mutant of human myeloid leukemia U937 cells. Exp Cell Res 1994; 215: 199–205. [DOI] [PubMed] [Google Scholar]
  • 31. Sakamoto H, Mashima T, Kizaki A, Dan S, Hashimoto Y, Naito M, Tsuruo T. Glyoxalase I is involved in resistance of human leukemia cells to antitumor agent‐induced apoptosis. Blood 2000; 95: 3214–8. [PubMed] [Google Scholar]
  • 32. Sakamoto H, Mashima T, Sato S, Hashimoto Y, Yamori T, Tsuruo T. Selective activation of apoptosis program by S‐p‐bromobenzylglutathione cyclo‐pentyl diester in glyoxalase I‐overexpressing human lung cancer cells. Clin Cancer Res 2001; 7: 2513–8. [PubMed] [Google Scholar]
  • 33. Thornalley PJ. The glyoxalase system: new developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem. J 1990; 269: 1–11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Lo TW, Westwood ME, McLellan AC, Selwood T, Thornalley PJ. Binding and modification of proteins by methylglyoxal under physiological conditions. A kinetic and mechanistic study with N alpha‐acetylarginine, N‐alpha‐acetylcysteine, and N‐alpha‐acetyllysine, and bovine serum albumin. J Biol Chem 1994; 269: 32299–305. [PubMed] [Google Scholar]
  • 35. Thornalley PK. Esterification of reduced glutathione. Biochem J 1991; 275: 535–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Godbout JP, Pesavento J, Hartman ME, Manson SR, Freund GG. Methylglyoxal enhances cisplatin‐induced cytotoxicity by activating protein ki‐nase Cδ. J Biol Chem. 2002; 277: 2554–61. [DOI] [PubMed] [Google Scholar]
  • 37. Van Herreweghe F, Mao J, Chaplen FW, Grooten J, Gevaert K, Vandekerck‐hove J, Vancompernolle K. Tumor necrosis factor‐induced modulation of glyoxalase I activities through phosphorylation by PKA results in cell death and is accompanied by the formation of a specific methylglyoxal‐derived AGE. Proc Natl Acad Sci USA 2002; 99: 949–54. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Sakamoto H, Mashima T, Yamamoto K, Tsuruo, T. Modulation of heat‐shock protein 27 (Hsp27) anti‐apoptotic activity by methylglyoxal‐modifica‐tion. J Biol Chem. 2002; 277: 45770–5. [DOI] [PubMed] [Google Scholar]
  • 39. Vanhaesebroeck B, Alessi DR. The PI3K‐PDK1 connection: more than just a road to PKB. Biochem J 2000; 346: 561–76. [PMC free article] [PubMed] [Google Scholar]
  • 40. Fujita N, Sato S, Katayama K, Tsuruo T. Akt‐dependent phosphorylation of p27Kipl promotes binding to 14–3–3 and cytoplasmic localization. J Biol Chem. 2002; 277: 28706–13. [DOI] [PubMed] [Google Scholar]
  • 41. Sato S, Fujita N, Tsuruo T. Modulation of Akt kinase activity by binding to Hsp90. Proc Natl Acad Sci USA 2000; 97: 10832–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Fontana J, Fulton D, Chen Y, Fairchild TA, McCabe TJ, Fujita N, Tsuruo T, Sessa WC. Domain mapping studies reveal that the M domain of hsp90 serves as a molecular scaffold to regulate Akt‐dependent phosphorylation of endothelial nitric oxide synthase and NO release. Circ Res 2002; 90: 866–73. [DOI] [PubMed] [Google Scholar]
  • 43. Fujita N, Sato S, Ishida A, Tsuruo T. Involvement of Hsp90 in signaling and stability of 3‐phosphoinositide‐dependent kinase‐1. J Biol Chem 2002; 277: 10346–53. [DOI] [PubMed] [Google Scholar]
  • 44. Basso AD, Solit DB, Munster PN, Rosen N. Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overex‐press HER2. Oncogene 2002; 21: 1159–66. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45. Bachelder RE, Wendt MA, Fujita N, Tsuruo T, Mercurio AM. The cleavage of Akt/PKB by death receptor signaling is an important event in detachment‐induced apoptosis. J Biol Chem 2001; 276: 34702–7. [DOI] [PubMed] [Google Scholar]
  • 46. Rokudai S, Fujita N, Hashimoto Y, Tsuruo T. Cleavage and inactivation of antiapoptotic Akt/PKB by caspases during apoptosis. J Cell Physiol 2000; 182: 290–6. [DOI] [PubMed] [Google Scholar]
  • 47. Sato S, Fujita N, Tsuruo T. Interference with PDKl‐Akt survival signaling pathway by UCN‐01 (7‐hydroxystaurosporine). Oncogene 2002; 21: 1727–38. [DOI] [PubMed] [Google Scholar]
  • 48. Nakashio A, Fujita N, Rokudai S, Sato S, Tsuruo T. Prevention of phos‐phatidylinositol 3'‐kinase‐Akt survival‐signaling pathway during topotecan‐induced apoptosis. Cancer Res 2000; 60: 5303–9. [PubMed] [Google Scholar]
  • 49. Nakashio A, Fujita N, Tsuruo T. Topotecan inhibits VEGF‐ and bFGF‐in‐duced vascular endothelial cell migration via downregulation of PI3K‐Akt signaling pathway. Int J Cancer 2002; 98: 36–41. [DOI] [PubMed] [Google Scholar]
  • 50. Nakanishi K, Sakamoto M, Yasuda J, Takamura M, Fujita N, Tsuruo T, Toda S, Hirohashi S. Critical involvement of the phosphatidylinositol 3‐kinase/ Akt pathway in anchorage‐independent growth and hematogenous intrahe‐patic metastasis of liver cancer. Cancer Res 2002; 62: 2971–5. [PubMed] [Google Scholar]

Articles from Cancer Science are provided here courtesy of Wiley

RESOURCES